ACR Infusion Guidance During COVID-19 Crisis
During the COVID-19 outbreak, rheumatology practices and patients have concerns about the
continued safety of office-administered therapies. Certain rheumatology patients may be among
the high-risk population for poor COVID-19 outcomes, and this may impact the risk and benefit
considerations for their ongoing treatments to include office administered therapies.
The ACR provides the following guidance for practices to continue to operate essential infusion
services utilizing CDC recommendations, to keep their patients and team members safe during
the COVID-19 crisis.